Bratislava-Dentons, together with Kirkland & Ellis and Bär & Karrer, has advised SK Capital LP on its acquisition of Swixx BioPharma Holding AG in a transaction valuing the company at over €1.5 billion.

SK Capital is a New York-based private investment firm focused on life sciences, specialty materials, and ingredients, managing approximately US$10 billion in assets. Swixx BioPharma operates in 45 countries across Europe, Eurasia, the Middle East, and Latin America and is one of the fastest-growing independent biopharma commercialization platforms serving underserved and hard-to-reach markets.

A cross-border Dentons team advised from seven jurisdictions - Ireland, Slovakia, Czech Republic, Poland, Kazakhstan, Colombia and Panama. Dublin-based partner Louise Hodnett led the Dentons' team with support from legal advisor Sophie Chan in Ireland; partner Juraj Gyárfáš and senior associate Michal Záthurecký in Bratislava; partner Tomáš Bílek in Prague; partner Pawel Grabowski in Warsaw; partner Gani Ashimkhan in Almaty; partner Mauricio Borrero in Bogota; and partner Gisela Porras in Panama City.

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com